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Abstract Cardiac failure is a major cause of mortality and
morbidity worldwide, since the standard treatment for car-
diac failure in the clinical practice is chiefly to focus on
removal of insults against the heart or minimisation of ad-
ditional factors to exacerbate cardiac failure, but not on re-
generation of the damaged cardiac tissue. A synthetic
prostacyclin agonist, ONO-1301, has been developed as a
long-acting drug for acute and chronic pathologies related to
regional ischaemia, inflammation and/or interstitial fibrosis
by pre-clinical studies. In addition, poly-lactic co-glycolic
acid-polymerised form of ONO-1301, ONO-1301SR, was
generated to achieve a further sustained release of this drug
into the targeted region. This unique reagent has been shown
to act on fibroblasts, vascular smooth muscle cells and en-
dothelial cells in the tissue via the prostaglandin IP receptor
to exert paracrinal release of multiple protective factors,
such as hepatocyte growth factor, vascular endothelial
growth factor or stromal cell-derived factor-1, into the ad-
jacent damaged tissue, which is salvaged and/or regenerated
as a result. Our laboratory developed a new surgical ap-
proach to treat acute and chronic cardiac failure using a
variety of animal models, in which ONO-1301SR is directly
placed over the cardiac surface to maximise the therapeutic
effects and minimise the systemic complications. This re-
view summarises basic and pre-clinical information of
ONO-1301 and ONO-1301SR as a new reagent to enhance
tissue salvage and/or regeneration, with a particular focus on
the therapeutic effects on acute and chronic cardiac failure
and underlying mechanisms, to explore a potential in
launching the clinical study.
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Abbreviations
ANP Atrial natriuretic peptide
bFGF Basic fibroblast growth factor
BM Bone marrow
cAMP Cyclic adenosine monophostate
GLP Good laboratory practice
HGF Hepatocyte growth factor
HUVEC Human umbilical vein endothelial cell
LV Left ventricle
MI Myocardial infarction
NHDF Normal human dermal fibroblast
PAH Pulmonary arterial hypertension
PLGA Poly-lactic co-glycolic acid
SDF Stromal cell-derived factor
TGF Transforming growth factor
VEGF Vascular endothelial growth factor
Introduction
Cardiac failure is the major cause of mortality and mor-
bidity worldwide [1]. Since cardiac tissue has a limited
regenerative capacity, any insults against the heart cause an
irreversible myocardial damage dependent upon nature and
magnitude of the insult, consequently inducing acute and/
or chronic cardiac failure. Current standard to treat cardiac
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failure is therefore to focus on removal of the insult itself,
such as reperfusion of the ischaemic tissue or struc-
tural/physiological correction by catheter and/or surgical
interventions [2], or minimisation of the additional factors
to exacerbate the myocardial damage, such as inhibition of
renin–angiotensin–aldosterone system [3, 4] or sympa-
thetic nerve activities [5, 6]. Nonetheless, treatment of
cardiac failure is not fully established [7], indicating that it
may be therapeutically effective to target on different
mechanisms underlying development of cardiac failure,
such as enhancement of cardiac tissue salvage and/or re-
generation [5].
It has been shown that cardiac-targeted gene transduc-
tion of pro-angiogenic/anti-inflammatory factors, such as
hepatocyte growth factor (HGF), vascular endothelial
growth factor (VEGF) or stromal cell-derived factor
(SDF)-1, enhances up-regulation of these factors in the
myocardium to contribute to tissue salvage and/or regen-
eration, consequently inducing functional recovery in an
array of the animal models of cardiac failure [8]. Moreover,
transplantation of somatic tissue-derived stem/progenitor
cells into the heart, such as bone marrow or skeletal
muscle-derived cells, persistently induces up-regulation of
the pro-angiogenic/anti-inflammatory factors in the my-
ocardium, contributing to functional recovery [9, 10]. It
was thus warranted that any treatments targeting intramy-
ocardial up-regulation of pro-angiogenic/anti-inflammatory
factors would be promising to enhance myocardial salvage
and/or regeneration. In clinical studies, feasibility, safety
and therapeutic efficacy of the somatic tissue-derived cell
transplantation therapy was established for cardiac failure;
however, this treatment has failed to gain a status as the
standard in the clinical practice to date for a variety of
potential reasons [9, 11]. Firstly, reported magnitude of
therapeutic effects is modest, potentially related to limited
retention/survival of the transplanted cells and/or limited
regeneration capacity of the targeted cardiac tissue [10,
12]. Secondly, additional processes to prepare the cells are
required in the routine clinical practice, which would not
overweigh the therapeutic benefits expected by the cell
transplantation therapy. It is therefore theorised that ‘‘the
shelf-stored drug’’ which has similar therapeutic effects to
the cell transplantation therapy would be more widely used,
potentially accepted as the standard, regeneration-based
therapy for cardiac disease in the clinical practice [13].
Prostaglandins and their derivatives are endogenous au-
tacoids produced by cyclooxygenase-related arachidonic
acid cascade, contributing to vasodilatation [14], inhibition of
platelet aggregation or anti-inflammation [15] in response
against local tissue damage. Of a variety of synthetic agonists
or antagonists of this cascade that were developed as a
drug, ONO-1301 (7,8-dihydro-5-[(E)-[[a-(3-pyridyl)-benzyli-
dene]aminooxy]ethyl]-1-naphthyloxy]acetic acid) was
synthesised as a small molecular weight compound having
prostacyclin IP receptor agonistic and thromboxane A2
synthase inhibitory activities (Fig. 1) [16–19]. ONO-1301
was initially developed as an anti-platelet drug; however, a
number of the basic studies including those from our
laboratory documented that a very small dose of ONO-1301
activates endothelial cells, vascular smooth muscle cells and
fibroblasts to release multiple pro-angiogenic/anti-inflam-
matory factors from their cytoplasm [16, 20–23]. In addition,
ONO-1301 has several theoretical advantages as a drug over
other synthetic prostaglandin agonists, such as beraprost,
epoprostenol, iloprost or treprostinil, since ONO-1301 has
been shown to exert long-lasting prostacyclin activities [16,
24, 25]. Moreover, poly-lactic co-glycolic acid (PLGA)-
polymerised form of ONO-1301, ONO-1301SR, was de-
veloped to achieve a sustained-release ONO-1301-delivery-
system [16, 25]. This review summarises information and
knowledge regarding to ONO-1301 and ONO-1301SR as a
tissue regeneration-based drug for cardiac disease and pro-
poses prospect of ONO-1301 for new drug in chronic
pathologies.
Pharmacological activity of ONO-1301
and development of ONO-1301SR
ONO-1301 is prostacyclin IP receptor agonist with a
thromboxane A2 synthase inhibitory activity. ONO-
1301SR is a PLGA-polymerised ONO-1301 to achieve a
sustained-release system [25]. These products have been
shown to have therapeutic effects on a variety of cardiac
pathologies via cytokines-induced salvage and/or regen-
eration of damaged cardiac tissue. This section documents
characteristics and pharmacological activity of ONO-1301
and ONO-1301SR in vitro. In addition, other prostaglandin
agonists under development are discussed in comparison
with ONO-1301.
Characteristics of ONO-1301
ONO-1301 is a synthetic prostacyclin IP receptor agonist
lacking the typical prostanoid structures, including a five-
membered ring and allylic alcohol, which are rapidly
metabolised by 15-hydroxyprostaglandin dehydrogenase
in vivo (Fig. 1) [16]. It is thus indicated that ONO-1301 is a
chemically stable structured prostacyclin agonist. In addi-
tion, ONO-1301 has a 3-pyridine radical to exert a throm-
boxane A2 synthase inhibitory activity, which induces an
intrinsic prostaglandin I2 synthesis-promoting effect to
augment the IP receptor agonistic activity [16]. Therefore,
this unique structure of ONO-1301 has been shown to pro-
duce a long-lasting prostacyclin activity with little drug re-
sistance compared to other prostacyclin agonists used in the
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clinical settings [24], proposing the advantage of this new
drug for acute and chronic pathologies that are related to
ischaemia, inflammation and/or fibrosis. In addition, it was
reported that ONO-1301 is inactivated by oxidation in the
liver within 3–4 h [24], indicating a wide utility of this
product as a drug in the clinical settings.
Pharmacological activity of ONO-1301
It has been shown that ONO-1301 agonises the IP receptor
expressed in a variety of the cells, such as fibroblast, vas-
cular smooth muscle cell or endothelial cell, to up-regulate
expression of multiple factors, such as VEGF, HGF or
SDF-1, in vitro [16]. The effects of ONO-1301 as a cy-
tokine inducer were shown to be mediated at least in part
by elevation of intracellular cyclic adenosine monophos-
phate (cAMP) [16, 26]. In addition, extracellularly released
factors by ONO-1301 have been shown to enhance a tube-
like formation of human umbilical vein endothelial cells
(HUVECs) co-cultured with normal human dermal fi-
broblasts (NHDF) in vitro [27], indicating a pro-angiogenic
property of ONO-1301. In addition, it was reported that
NHDF stimulated by ONO-1301 enhanced migration of
bone marrow (BM)-derived cells mediated by extracellu-
larly released SDF-1, in vitro [20], suggesting that ONO-
1301 may have an effect to enhance migration of circu-
lating BM cells into the targeted territory contributing to
BM cell-mediated tissue salvage and/or regeneration.
Development of ONO-1301SR to establish a sustained-
release drug-delivery system
While ONO-1301 has been shown to have a long-lasting
prostacyclin agonistic effect compared to the other
prostacyclin agonists, it would be further useful and
beneficial to develop a sustained-release drug-delivery
system of ONO-1301 to achieve a further prolonged
prostacyclin agonistic effects on the targeted territory of
acute and chronic pathologies. For this purpose, ONO-1301
was polymerised with PLGA microspheres that are proven
to be biocompatible and biodegradable, used as controlled
delivery system for proteins or drugs in clinical settings
[16, 25]. As a result, this ONO-1301SR product was shown
to be hydrolysed at the site of administration to linearly
release ONO-1301 into the adjacent tissue with a modest
initial burst (Fig. 2). In addition, duration of ONO-1301
release can be adjusted by modifying the molecular weight
of PLGA, the lactic/glycolic acids ratio or the particle size
to achieve optimum effects, depending upon the targeted
























Fig. 1 Prostacyclin has the
prostanoid structure including a
five-membered ring (indicated
as blue circle) and an allylic
alcohol (indicated as orange
circle), which are rapidly
metabolised in vivo. In contrast,
a synthetic selective agonist of
prostacyclin, ONO-1301, lacks
the prostanoid structure, while
this reagent has the structure
having a thromboxane A2
inhibitory activity (indicated as
purple circle). Other selective
prostacyclin agonists, such as
iloprost or beraprost, have the
prostanoid structure (indicated
as blue and orange circles)
without thromboxane A2
inhibitory activity
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Other prostaglandin agonists under development
Agonists of prostagrandins are theoretically therapeutic for
acute and chronic pathologies associated with tissue is-
chaemia, inflammation and/or interstitial fibrosis. Xiao
et al. [28] reported in 2004 that prostaglandin EP4 receptor
agonist, ONO-4819, was effective in attenuating myocar-
dial ischaemia–reperfusion injury via elevation of intra-
cellular cAMP concentration in noncardiomyocytes. In
addition, this product was shown to have a positive effect
on bone regeneration [29–39] or nerve root angiogenesis
[40], and have a protective effect against acute liver injury
[41], skin injury [42] or renal tubulointerstitial fibrosis [43].
Of note, ONO-4819 is under the clinical study for treating
medically refractory ulcerative colitis [44], though the re-
sult has not been reported. Another EP4 receptor agonist,
EP4RAG, has been shown to have a protective effect
against ischaemia–reperfusion myocardial injury [45],
cardiac allograft transplantation-related inflammation [46]
or experimental autoimmune myocarditis [47]. Despite
several similar products to ONO-1301, it appears that
sustained-release form of prostagrandin agonist has been
developed only in ONO-1301 to date.
Evidence of cardiac tissue salvage/regeneration
by ONO-1301SR
Therapeutic effects of ONO-1301SR have been tested on a
variety of cardiac pathologies, such as acute and chronic
myocardial infarction (MI), cardiomyopathy, cardiac allo-
graft disease post-transplantation or myocarditis. As a
result, ONO-1301SR treatment showed positive effects on
these pathologies by different mechanisms from other ex-
isting treatments that are used in the clinical settings,
indicating that ONO-1301SR is a potential new drug for a
variety of cardiac diseases. This section summarises pre-
vious reports that document effects of ONO-1301 or ONO-
1301SR on each cardiac pathologies.
Effects of ONO-1301SR on acute MI
Ischaemic insult against the heart by limiting coronary
perfusion rapidly induces intracellular lactic acidosis in the
cardiac myocytes, which leads to reduction of cellular
contractility and subsequent necrotic cell death, conse-
quently generating a state of ‘‘acute MI’’ [48, 49]. An array
of debris from the dead cells or ‘‘danger signals’’ from cells
that confront with the ischaemia activate inflammatory
reactions, including accumulation of circulating cells or
activation of residential cells in the cardiac tissue that
consequently determines an area of ‘‘infarct region,’’ where
cardiac myocytes were lysed and replaced by fibrous
components [50, 51]. In addition, border area between the
infarct area and the area with sufficient blood supply
confronts with persistent ischaemia that progressively
widen the infarct region [51].
Treatment for the acute MI is therefore reperfusion of
the ischaemic area to supply sufficient blood flow into the
tissue [52]. It is, however, known that early reperfusion
induces intracellular calcium overload, overproduction of
superoxides and their derivatives and mitochondrial per-
meability transition pore opening in the cardiac myocytes,
which consequently yields rapid cell death that often
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Fig. 2 Representative electron micrographic images of ONO-1301SR, which is a PLGA-polymerised form of ONO-1301, after production at
37 C in vitro. Structure of the microspheres is gradually degraded over 28 days
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causes lethal ventricular arrhythmia, and importantly ex-
acerbates inflammatory response in the reperfused area [53,
54]. Despite a number of attempts, additional treatments
that effectively reduce ischaemia–reperfusion cardiac in-
jury have not been developed [53]. Among the agents that
activate myocyte receptors, such as adenosine [55],
bradykinin [56], opioids [57], glucagon-like peptide 1 [58],
atrial natriuretic peptide (ANP) [59], erythropoietin [60] or
insulin [61], intravenous infusion of adenosine and ANP
showed positive, but not substantial, additional therapeutic
effects to direct percutaneous coronary intervention for
acute MI. In addition, effects of the agents that act intra-
cellularly, such as volatile anaesthetics [62], nitrates [63],
atorvastatin [64], delcasertib [65], nicorandil [59] or cy-
closporine [66], have not been proven by large randomised
studies. There are a number of other potential agents that
were or were not tested by large-scale human studies, such
as phosphodiesterase-5 inhibitors [67], superoxide dismu-
tase [68] or neutralising antibodies against adhesion
molecules such as P-selectin, intercellular adhesion mole-
cule-1 [69]. Importantly, these treatments are targeted to
effect on a single cellular and/or molecular process among
a variety of complicated dynamic processes related to is-
chaemic-reperfusion cardiac injury, potentially limiting the
overall therapeutic effects. In addition, delivery method of
the agents needs to be optimised depending upon the un-
derlying therapeutic mechanisms [68, 69].
In contrast, it has been shown that administration of
ONO-1301SR directly activates endothelial cells and vas-
cular smooth muscle cells through the IP receptor, to in-
duce paracrinal release of protective factors, such as HGF,
VEGF or SDF-1, into the damaged cardiac tissue. Naka-
mura et al. [27] first reported therapeutic effects of ONO-
1301SR on acute MI in 2007. They directly injected ONO-
1301SR into the myocardium that was subjected to is-
chaemia by left coronary artery ligation in mice. As a re-
sult, LV enlargement post-MI was ameliorated and survival
was improved by ONO-1301SR treatment, in association
with intramyocardially up-regulated HGF and VEGF. They
concluded that angiogenesis by ONO-1301SR-induced up-
regulation of multiple cytokines is the key therapeutic
mechanisms of this treatment for acute MI [27]. In addi-
tion, the same team reported the angiogenesis-related
positive effects of ONO-1301SR on acute MI with reper-
fusion using a rat model in 2012 [70]. Furthermore, our
group reported that ONO-1301SR treatment enhances re-
cruitment of bone marrow-derived cells into the ischaemic
myocardium via enhanced SDF-1/C-X-C chemokine re-
ceptor type 4 interaction in a murine acute MI model [20].
It was thus concluded that accumulation of bone marrow-
derived cells by ONO-1301SR treatment is an alternative
therapeutic mechanisms of this treatment, though role of
the accumulated cells needs to be clarified. Noticeably, our
group delivered ONO-1301SR into the heart in an atelo-
collagen-based sheet form [20], since it was considered that
direct injection of ONO-1301SR into the myocardium may
induce myocardial injury.
All of these reports suggest mechanisms of cardiac
salvage and/or regeneration in the ONO-1301SR treatment
for acute MI, such as angiogenesis by up-regulation of
multiple pro-angiogenic cytokines or recruitment of bone
marrow-derived cells. However, further basic studies are
necessary to thoroughly clarify the therapeutic mechanisms
of this treatment for acute MI. Moreover, these reports
indicate the therapeutic potential of ONO-1301SR for
treating acute MI in clinical settings, whereas delivery
method and dose of ONO-1301SR need to be optimised in
basic studies by the good laboratory practice (GLP)
standard.
Effects of ONO-1301SR on chronically failing heart
Chronic cardiac failure is a result of previous or continuous
insult against the heart, such as ischaemia, valvular
pathologies or genetic abnormalities. In this state, pressure
and/or volume overload in the heart continuously activates
a variety of cellular and molecular processes to remodel
ventricular structure, by which pressure and/or volume
overload is further exacerbated, to generate the viscous
cycle, ‘‘left ventricular (LV) remodelling’’ [5]. In addition,
humoral, hormonal and/or sympathetic nerve activities
further exacerbates pressure and/or volume overload to
affect progression of the LV remodelling.
Existing surgical treatments directly target pressure and/
or volume overloading by intervening valvular pathologies
or dilated ventricle, while existing medical treatments tar-
get hormonal and/or sympathetic nerve activities. On the
other hand, treatments targeting responsible cellular and
molecular processes for LV remodelling are under devel-
opment as represented by cell transplantation therapy [9,
10, 12]. It has been shown that transplantation of somatic
tissue-derived stem/progenitor cells, such as bone marrow-
derived cells or skeletal muscle-derived cells, into the
chronically failing heart enhanced native regeneration ca-
pacity by inducing constitutive expression of pro-angio-
genic factors or anti-fibrotic factors, consequently to
reverse LV remodelling, as reported by an array of pre-
clinical studies [9, 10, 12]. Treatment by ONO-1301SR
was also reported to induce similar therapeutic mechanisms
to the cell transplantation therapy in chronic failing heart in
pre-clinical studies as follows.
Iwata et al. [71] generated a chronic MI model in swine
by placing the ameroid constrictor in the left circumflex
artery (LCX) to induce MI. Four weeks later, they per-
formed direct epicardial injection of ONO-1301SR into the
infarct border area under LV electromechanical mapping
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guidance using a transcatheter system. As a result, ONO-
1301SR treatment enhanced collateral growth in relation to
increased number of the capillaries, attenuated collagen
fraction in the myocardial interstitium and reduced LV
volume, indicating that this treatment reversed the LV re-
modelling. They discussed that intramyocardially delivered
ONO-1301SR directly acted on the residential fibroblasts
to induce up-regulation of cardiotherapeutic factors such as
VEGF or HGF, which in turn activated the regeneration
process in the chronic MI heart [71].
Our group generated a chronic MI model in canine by
permanently ligating left coronary artery [22]. Subse-
quently, ONO-1301SR-immersed atelocollagen sheet was
placed over the LV surface of this model. ONO-1301SR
treatment induced functional recovery compared to sham
treatment as assessed by standard and speckle-tracking
echocardiography and cardiac catheterisation studies, in
association with up-regulated HGF, VEGF or SDF-1. Im-
portantly, this study showed increased myocardial blood
flow by ONO-1301SR treatment as assessed by 13N-am-
monia positron emission tomography study [22], indicating
that pro-angiogenic effects of ONO-1301SR augment
myocardial blood flow to induce functional recovery in
ischaemic cardiomyopathy (Fig. 3).
Effects of ONO-1301SR on dilated cardiomyopathy were
tested by Hirata’s group and our group. Hirata et al. [72]
subcutaneously injected ONO-1301SR into the hamsters
having genetically determined dilated cardiomyopathy. As a
result, ONO-1301SR-treated hamsters showed a preserved
cardiac function in relation to reduced fibrous components
and increased capillary network in the myocardial intersti-
tium, suggesting a therapeutic potential of systemic delivery
of ONO-1301SR into the dilated cardiomyopathy-related
chronic cardiac failure [72].
In contrast, our group used the rapid-pacing-induced
canine model [23] and the delta-sarcoglycan-deficient
hamster model [21] that was a different model from that of
Hirata’s group. Our group directly delivered into the heart
in order to maximise the therapeutic effects of this reagent
and minimise systemic complications. Firstly, ONO-
1301SR was intramyocardially injected in rapid LV-paced
canines with their LV ejection fraction being\40 % [23].
As a result, global and regional LV functions were recov-
ered in 4 weeks after the treatment, in association with
increased microvessel number, decreased myocyte di-
ameter and decreased fibrous component in the LV my-
ocardium [23]. However, the direct intramyocardial
injection of ONO-1301SR used in this report was con-
cerned by inconsistent delivery of the reagent and injec-
tion-related myocardial injury.
Therefore, in the subsequent study, ONO-1301SR im-
mersed into the atelocollagen sheet was simply placed on
the LV surface of hamster model of dilated cardiomyopa-
thy [21]. This delivery method would achieve a consistent
delivery of the reagent into the heart and minimum injury




















Fig. 3 Schematic representation of proposed mechanisms underlying
ONO-1301SR-immersed sheet placement therapy for treating dam-
aged cardiac tissue. ONO-1301 is linearly released from the ONO-
1301SR by hydrolysis and infiltrated into the cardiac tissue. IP
receptor-expressing cardiac cells, such as vascular smooth muscle
cells, fibroblast and endothelial cells, are activated by ligation of
ONO-1301 to paracrinally release protective factors, such as VEGF,
HGF or SDF-1
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affected by ONO-1301SR might be theoretically limited.
As a result, myocardial vascular network was globally and
homogeneously better developed in the ONO-1301SR-
treated hamsters with a substantial survival benefit in as-
sociation with up-regulated cardiotherapeutic factors such
as VEGF, HGF or SDF-1 [21]. Importantly, this study
showed a consistently heart-dominant elevation of ONO-
1301 concentration until 4 weeks after the ONO-1301SR
administration [21]. It was thus indicated that placement of
ONO-1301SR-immersed collagen sheet over the LV sur-
face act on the entire LV contributing to global functional
recovery. These two studies proved the concept that local
delivery of ONO-1301SR into the heart contributes to
functional recovery and survival benefit in dilated car-
diomyopathy-related chronic cardiac failure (Fig. 3).
Effects of ONO-1301SR on other cardiac pathologies
ONO-1301SR was thus shown to have anti-inflammatory,
pro-angiogenic and anti-fibrotic effects on acute and
chronic cardiac pathologies via up-regulation of a variety
of cardiotherapeutic cytokines and chemokines. Further-
more, positive effects of ONO-1301SR were shown in
other cardiac pathologies such as cardiac graft disease post-
transplantation [73] or autoimmune myocarditis.
Suzuki et al. [73] subcutaneously injected ONO-1301SR
into the mice that were subjected to heterotopic cardiac
allograft transplantation in the aim to test the effects of
ONO-1301SR on acute and chronic graft-host disease. This
treatment was effective in chronic rejection as shown in the
reduced myocardial fibrosis in a class II mismatch com-
bination, but not effective in acute rejection in a full al-
lomismatch combination, suggesting that ONO-1301SR
might be a potential new drug for chronic rejection post-
cardiac allograft transplantation. Hirata et al. [74] reported
that daily intake of ONO-1301 (not PLGA-polymerised SR
form, but bulk substance) suppressed a progression of LV
remodelling chiefly via up-regulation of HGF in a rat au-
toimmune myocarditis model. It was indicated that HGF
plays a critical role in LV remodelling in this model and
that ONO-1301 may be an ideal inducer of HGF in the
myocardium. Further studies are warranted to prove the
positive effects of ONO-1301 on other cardiac pathologies
related to acute/chronic inflammation, microvascular dys-
function or fibrous accumulation in the myocardium, such
as hypertensive cardiac disease.
Towards clinical studies of ONO-1301SR for treating
cardiac disease
Although positive effects of ONO-1301SR treatment were
proven on a variety of cardiac pathologies, such as acute
MI, idiopathic dilated cardiomyopathy, ischaemic car-
diomyopathy, cardiac allograft disease post-transplantation
or fulminant myocarditis, it is a key of success of this
treatment to optimise delivery method of ONO-1301 for
each target pathology in clinical study. This section dis-
cusses suitable target pathology and delivery method of
this reagent, and studies necessary for the first-in-human
study. In addition, potential methods to enhance the
therapeutic effects of ONO-1301 are discussed in the
prospect of clinical application.
Pathology-specific ONO-1301SR delivery
for the clinical study
It has been shown that both systemic and local delivery of
the ONO-1301SR potentially contributes to the therapeutic
benefits for acute and chronic cardiac disease. However,
optimal mode of the delivery in the clinical settings would
be dependent upon the pathology and, most importantly,
the standard treatment for the pathology in the routine
clinical practice.
Since the standard treatment for the acute MI is the
prompt reperfusion of the occluded coronary arteries by
percutaneous transcatheter approach, direct intramyocar-
dial injection of ONO-1301SR by transcatheter approach at
the time of reperfusion may be ideal, although further basic
studies using a large animal model are necessary. In ad-
dition, subcutaneous ONO-1301SR injection or oral intake
of ONO-1301 would be optional mode of the ONO-
1301SR delivery as an additional treatment for acute MI to
the standard reperfusion therapy.
The standard treatment for ischaemic and non-ischaemic
dilated cardiomyopathy is the intensive combination of
medical and interventional treatments. Addition of subcu-
taneous ONO-1301SR injection or oral ONO-1301 intake
to the optimal medical management would augment the
therapeutic effects of the standard medical treatment.
Placement of ONO-1301SR over the cardiac surface,
which has been intensively developed by our laboratory,
may be added at the time of coronary artery bypass grafting
and/or mitral valve surgery for ischaemic and non-is-
chaemic dilated cardiomyopathy. Addition of the ONO-
1301SR placement therapy at the time of ventricular assist
device implantation surgery might be effective in enhanc-
ing functional recovery to achieve ‘‘bridge-to-recovery’’
for dilated cardiomyopathy or fulminant myocarditis.
Head-to-head comparison study for the therapeutic ef-
fects between placement over the heart and subcutaneous
injection of ONO-1301SR has not been reported. However,
it may be theorised that enhanced effects will be achieved
by the local placement which maximise ONO-1301 deliv-
ery into the targeted area with minimal systemic effects,
since paracrinal actions of the effector cells are augmented
Heart Fail Rev (2015) 20:401–413 407
123
in positive relation to the magnitude of the ONO-1301
stimuli [20, 21, 23].
Studies necessary for the clinical study
Once the target pathology and the delivery mode of the
ONO-1301SR treatment were decided, dose-optimisation
study ideally using a large animal model is necessary to
launch the clinical study. Degree of therapeutic effects and
systemic complications such as hypotension, bleeding or
diarrhoea, in addition to plasma and cardiac ONO-1301
level, need to be investigated depending upon the dose of
ONO-1301SR. Moreover, toxicity test in the GLP standard
is necessary by using a large animal model over 3 months,
since it was shown that ONO-1301 is extinguished from the
body by 1 month [21].
Enhancing positive effects of ONO-1301SR treatment
on cardiac pathologies
Therapeutic mechanisms of ONO-1301SR were to induce
constitutive up-regulation of a variety of protective factors,
such as VEGF, HGF or SDF-1, which are shared by so-
matic tissue-derived stem/progenitor cell transplantation
therapy. One may be concerned by durability of the
therapeutic efficacy, since all administered ONO-1301 as a
SR form is inactivated by 4 weeks. Although newly formed
vasculatures by 4 weeks might remain to contribute to the
myocardial blood flow and thus the functional recovery
despite extinction of paracrinal stimuli, as seen in the tis-
sue-derived stem/progenitor cell-based therapy [75], addi-
tional concomitant treatments may augment the positive
effects and prolong its durability. One approach would be
combination with the treatments that contribute to cardiac
function by a different mechanism from ONO-1301SR,
while the other approach may be combination with treat-
ments whose mechanisms are similar to ONO-1301SR.
Our group developed hybrid therapy by combination of
ONO-1301SR delivery and cardiac support mesh net de-
vice placement [22]. It has been shown that placement of
cardiac support net over the ventricles mechanically re-
duces diastolic LV wall stress to inhibit progression of the
LV remodelling, whereas clinical studies of cardiac support
net for treating chronically failing heart failed to show
survival benefits despite positive effects on the LV volume
[76]. This inconsistent result of cardiac support net device
would be explained by a lack of biological effects in this
treatment. In contrast, ONO-1301SR contributes to recov-
ery of cardiac function by the biological effects, not by
mechanical effects. It was therefore theorised that combi-
nation of ONO-1301SR and cardiac support net placement
would augment the therapeutic effects of either treatment.
To test this hypothesis, our laboratory developed a hybrid
device consisting of biodegradable polyglycolic acid-based
cardiac support net and ONO-1301SR-immersed atelocol-
lagen sheet for treating a canine chronic MI model [22]. As
a result, the hybrid device elicited a greater reversal of the
MI-inducing LV remodelling than either single treatment,
indicating the potential of this device for chronic cardiac
failure [22].
Transplantation of somatic tissue-derived stem/pro-
genitor cells has been shown to yield a functional recovery
of the failing heart via a similar mechanism to the ONO-
1301SR treatment, though therapeutic effects of the cell
transplantation therapy are reportedly limited by poor ini-
tial retention and long-term survival of the transplanted
cells [75, 77, 78]. One may claim that head-to-head com-
parison study in the therapeutic effects of the two treat-
ments would be clinically important. This pre-clinical
study may not be, however, justified by a large number of
model animals used to gain statistical significance, since
previous studies showed that both treatments improved
ejection fraction by 5–10 % [22, 79]. Rather, addition of
the ONO-1301SR placement therapy to the cell trans-
plantation therapy may prolong the regenerative effects for
the cardiac tissue, depending upon expression of IP re-
ceptor and subsequent intracellular signalling in the trans-
planted cells. Further studies are necessary to test this
hypothesis.
Omentum is an abdominal organ, mobilised to be at-
tached to the abdominal organ/tissue in response to the
tissue damage/injury. Multiple pro-angiogenic factors are
known to be abundantly expressed in the omentum, con-
tributing to regeneration and/or healing of the damaged/
injured tissue/organ. This unique character of the omentum
was applied to develop a treatment for cardiac ischaemic
disease by mobilising to the cardiac surface in a pedicle
fashion [75, 80]. As a result, angiogenesis was induced in
the ischaemic/infarct territory of the cardiac tissue. Of note,
it was reported that omentum covering over the chronic
MI-heart with local sustained-delivery of basic fibroblast
growth factor (bFGF), but not without bFGF, induced a
new vascular network formation between the pedicle
omentum and the heart [75]. It is thus theorised that the
omentum covering with local delivery of ONO-1301SR
might be effective in augmenting regional blood flow in the
ischaemic cardiac tissue via formation of new vascular
networks in the heart.
ONO-1301/ONO-1301SR treatment for extracardiac
pathologies
ONO-1301 is theoretically effective in treating any acute
and chronic pathologies for which dysfunction of mi-
crovasculature or accumulation of fibrous components in
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the tissue/organ is responsible, as shown in the studies for
cardiac pathologies. In fact, use of this reagent was re-
ported to be effective in pulmonary arterial hypertension
(PAH), pulmonary fibrosis or chronic kidney disease.
Moreover, the effects of ONO-1301SR as a potent pro-
tective cytokines-inducer might be applied to other
pathologies, such as cerebral, liver or pancreatic patholo-
gies. This section summarises previous reports and poten-
tial target of ONO-1301SR treatment for extracardiac
pathologies. In addition, this section discusses a potential
of ONO-1301SR in combination with medical devices, to
accumulate further knowledge and information regarding
this unique product, exploring further applications.
ONO-1301SR treatment for lung disease
Since several prostagrandin agonists are the standard
treatment of primary and secondary PAH in the clinical
practice [81, 82], an ideal target pathology of ONO-1301
and/or ONO-1301SR treatment might be PAH or associ-
ated lung diseases. In fact, Kataoka et al. reported in 2006
that repeated subcutaneous administration of ONO-1301
attenuated monocrotaline-induced PAH in rats via the
long-lasting cAMP stimulation and thromboxane synthase
inhibition [83, 84]. Subsequently, Obata et al. [85] reported
in 2007 that a single subcutaneous injection of ONO-
1301SR resulted in attenuated pulmonary arterial pressure,
at least in part, through inhibition of vascular smooth
muscle cell proliferation in a rat monocrotaline-induced
PAH model. The same group reported in 2013 that oral
administration of ONO-1301 was therapeutic in monocro-
taline-induced PAH rats [86]. Moreover, Murakami et al.
[87] reported in 2006 that repeated subcutaneous admin-
istration of ONO-1301 attenuated bleomycin-induced pul-
monary fibrosis in mice.
Hayashi et al. [88] reported in 2010 that administration
of ONO-1301 was more therapeutic for ovalbumin-induced
asthma model in mice than beraprost. In addition, Kimura
et al. [89] tested the hypothesis that ONO-1301SR treat-
ment is effective in suppressing hyperresponsiveness, al-
lergic inflammation and remodelling of the airway. As a
result, they proved the anti-inflammatory and the reverse
remodelling effects of ONO-1301SR on chronic house dust
mite-induced asthma model in mice.
These results might warrant a potential of ONO-1301SR
treatment for PAH or asthma, of which chronic inflam-
mation is involved in the development of the pathologies,
in clinical practice. Further basic studies should be focused
on optimisation of the dose of ONO-1301SR or the ad-
ministration mode of ONO-1301SR, such as a single sub-
cutaneous injection, intermittent injections, or oral intake.
It may be proposed that intravenous injection of ONO-
1301SR would induce entrapment of the product in the
pulmonary arterioles or capillaries to achieve sustained
release of the ONO-1301, although intravenous injection
may carry a substantial risk of pulmonary embolism that
further exacerbates PAH or associated lung pathologies.
ONO-1301SR treatment for kidney diseases
Progression of chronic kidney disease is known to be
regulated by chronic inflammatory and fibrotic process in
the tubulointerstitium of the kidney. Anti-inflammatory
effects of ONO-1301 on nephritis was first reported by
Hayashi et al. in 1997 [90]. Subsequently, Yamasaki et al.
[91] reported that repeated injections of ONO1301SR were
effective in reducing renal fibrosis in diabetic nephropathy
rat model. In addition, Nasu et al. [92] reported in 2012 that
a single subcutaneous injection of ONO-1301SR into the
mice that were subjected to unilateral ureteral obstruction
yielded a suppression of interstitial fibrous components of
the obstructed kidney partly via inhibition of transforming
growth factor (TGF)-b, suggesting a potential of ONO-
1301SR for the chronic kidney disease, though further
studies to prove the safety, efficacy and further mechan-
isms underlie this treatment.
ONO-1301SR treatment for other organ pathologies
Although standard treatment of cerebral ischaemia is early
reperfusion, additional medical treatments that ameliorate
ischaemia–reperfusion injury would further improve the
outcome of the intervention. Hazekawa et al. [93] reported
in 2012 that a single subcutaneous injection of ONO-
1301SR into the rats that were subjected to repeated in-
duction of cerebral ischaemia yielded a short-term func-
tional and histopathological recovery. The same groups
reported in 2012 that repeated ONO-1301SR administra-
tion reduced ischaemic damage of rats that were subjected
to middle cerebral artery occlusion [94].
Acute liver injury is a life-threatening disorder, initiated
by a burst inflammation, followed by a complex inflam-
matory process. Since prompt treatment is known to im-
prove the outcome of this pathology, new ‘‘shelf-stored
drug’’ has been long sought. Xu et al. [95] reported in 2011
that intermittent oral administration of ONO-1301, not SR
product, ameliorated CCl4-induced acute hepatic injury in
mice partly via up-regulation of HGF. The same group
reported in 2013 that ONO-1301SR was effective in
treating CCl4-induced inflammatory chronic liver fibrosis
in mice [96]. Inflammation plays a key role in clinical and
pathological progression of chronic pancreatitis. Niina
et al. [97] reported in 2014 that ONO-1301SR inhibited
monocyte activity to suppress pancreatic fibrosis. These
reports indicate that ONO-1301SR may be therapeutically
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effective for acute and chronic pathologies related to is-
chaemia, inflammation and/or fibrosis in multiple organs.
A potential of ONO-1301SR in combination
with medical devices
Of the implantable medical devices that have been recently
developed, vascular stent has been widely used as the
standard treatment for atherosclerotic arterial stenosis or
aortic aneurysm [98]. In particular, stent graft implantation
of aortic aneurysm has improved clinical outcomes of this
pathology, though complications related to a poor attach-
ment of the stent and the native aortic wall have not been
fully resolved [99]. Since ONO-1301 has effects on tissue
healing and/or regeneration, it is hypothesised that local
delivery of ONO-1301 might strengthen the attachment
between the stent graft and the native aortic wall. To test
this hypothesis, our laboratory developed an aortic stent
graft that was coated with ONO-1301SR and implanted in
the thoracic aorta of canines [100]. As a result, the at-
tachment was physiologically and histopathologically
strengthened. This concept may be applicable to the tran-
scatheter aortic valve replacement, in which aortic valve
incompetence caused by suboptimal attachment of the
prosthesis and the native aortic annulus yields a negative
impact of this treatment [101].
Conclusions
Feasibility, safety and therapeutic efficacy of a synthetic
prostacyclin agonist, ONO-1301, and a sustained-release
form of ONO-1301, ONO-1301SR, have been tested in a
variety of acute and chronic pathologies related to is-
chaemia, inflammation and fibrosis of multiple organs in-
cluding the heart as pre-clinical studies. Major mechanisms
underlying the therapeutic effects were consistently to in-
duce release of multiple protective cytokines including
HGF, VEGF or SDF-1 from targeted fibroblasts, vascular
smooth muscle cells or endothelial cells, which enhance
salvage and/or regeneration of the damaged tissue, in-
cluding the heart.
Both acute and chronic cardiac failure related to is-
chaemic or non-ischaemic aetiologies would be a target of
this novel treatment. Since direct placement of ONO-
1301SR over the cardiac surface was suggested to be an
optimal treatment for chronic cardiac failure using this
product, launching the clinical study of this treatment is
warranted. In addition, oral administration of ONO-1301
would be a potential drug for chronic cardiac failure,
though further pre-clinical studies are needed in the GLP
standard.
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